Home > Publications database > Epstein-Barr Virus Serology Associated With Persistent Oral Human Papillomavirus Infections in Men. > print

001     303427
005     20250809114439.0
024 7 _ |a 10.1111/jop.70015
|2 doi
024 7 _ |a pmid:40772503
|2 pmid
024 7 _ |a 0300-9777
|2 ISSN
024 7 _ |a 0904-2512
|2 ISSN
024 7 _ |a 1600-0714
|2 ISSN
037 _ _ |a DKFZ-2025-01652
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Rinne, Sanni
|0 0009-0002-8268-7485
|b 0
245 _ _ |a Epstein-Barr Virus Serology Associated With Persistent Oral Human Papillomavirus Infections in Men.
260 _ _ |a Oxford [u.a.]
|c 2025
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1754660961_12815
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a epub
520 _ _ |a Most people acquire Epstein-Barr virus (EBV) and certain human papillomaviruses (HPVs) during their lifetime. HPV-related oropharyngeal carcinomas have increased in recent decades, particularly among men. The role of coinfection with viruses like EBV on HPV outcomes is unclear. We investigated potential associations between EBV serology and longitudinal outcomes of oral HPV infections in men.This study included 119 men from the Finnish Family HPV Study who were followed up for 3 years. Blood and oral cavity samples were collected at baseline, 12-, 24-, and 36-month follow-up visits. HPV was genotyped with the Multimetrix assay, and the serum IgG antibodies of EBV proteins Zebra, EA-D, EBNA, and VCAp18 were measured with fluorescent bead-based multiplex serology. Univariate regression analysis was used to measure the strength of the association between different variables.Most participants (99.2%; n = 118) were EBV-seropositive with stable antibody titers throughout the follow-up. Self-reported history of atopy was positively associated with elevated EBNA-1 levels, with OR 7.43 (95% CI: 1.39-39.76). EBV seropositivity with high titers and elevated EA-D levels alone increased the risk of type-specific oral HPV persistence for Types 16, 18, 33, and 51, with OR 4.20 (95% CI: 1.09-16.19) and OR 6.23 (95% CI: 1.19-32.75), respectively.Most of the participants were EBV-seropositive as expected. Elevated EA-D antibody levels and being EBV-seropositive with high titers significantly increased the risk of type-specific oral HPV persistence among these men.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a EBV antibodies
|2 Other
650 _ 7 |a EBV serology
|2 Other
650 _ 7 |a Epstein–Barr virus (EBV)
|2 Other
650 _ 7 |a human papillomavirus (HPV)
|2 Other
650 _ 7 |a oral HPV infections
|2 Other
700 1 _ |a Michels, Birgitta
|0 P:(DE-He78)b48bfd64120195b64b5f11d32ce5ed5e
|b 1
|u dkfz
700 1 _ |a Butt, Julia
|0 P:(DE-He78)31d7c3e829be03400641f80b821ef728
|b 2
|u dkfz
700 1 _ |a Syrjänen, Kari
|b 3
700 1 _ |a Grenman, Seija
|b 4
700 1 _ |a Waterboer, Tim
|0 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
|b 5
|u dkfz
700 1 _ |a Syrjänen, Stina
|b 6
700 1 _ |a Louvanto, Karolina
|b 7
773 _ _ |a 10.1111/jop.70015
|g p. jop.70015
|0 PERI:(DE-600)2026385-5
|p nn
|t Journal of oral pathology & medicine
|v nn
|y 2025
|x 0300-9777
909 C O |o oai:inrepo02.dkfz.de:303427
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)b48bfd64120195b64b5f11d32ce5ed5e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)31d7c3e829be03400641f80b821ef728
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-11
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-11
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J ORAL PATHOL MED : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-11
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-11
920 1 _ |0 I:(DE-He78)D320-20160331
|k D320
|l Infektionen und Krebs-Epidemiologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D320-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21